ADVM) on Monday reported a loss of $18.5 million in its second quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of 89 cents. The results exceeded Wall Street expectations.

- 6E10 dose of Ixo-vec selected for Phase 3 pivotal trials - LUNA 26-week interim analysis presented at ASRS 2024 demonstrating a potential best-in-class product profile of Ixo-vec, with similar efficacy and a favorable safety profile compared to OPTIC - LUNA 9-month landmark analysis and pivotal trial design update anticipated in 4Q 2024 - $173.8 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., Aug. 12, 2024 (GLOBE NEW

REDWOOD CITY, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 at 2:00 p.m. ET. The webcast of the firesi

REDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Ixo-vec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD. “The RMAT designation is based on the clinica

Here is how Adverum Biotechnologies (ADVM) and Medpace (MEDP) have performed compared to their sector so far this year.

- 6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks - Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control - Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled prophylaxis - Patient Preference Survey: 88% of patients indicate

The mean of analysts' price targets for Adverum Biotechnologies (ADVM) points to a 290.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Soc

REDWOOD CITY, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies, will participate in a fireside chat at TD Cowen’s Genetic Medicines & RNA Summit on Friday, June 21, 2024 at 10:00 a.m. ET. The webcast of the presentation may be a

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company’s executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company’s Board of Directors. Dr. Ozden has stepped down from the Company’s Board of Directors, with Dr. Kiss filling t